Hillevax Inc

NASDAQ HLVX

Data sourced from

and

Download Data

Hillevax Inc Days in Inventory for the Trailing 12 Months (TTM) ending March 31, 2024

Hillevax Inc Days in Inventory is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The days in inventory ratio measures the average number of days it takes for a company to sell its inventory. It is calculated by dividing 365 by the ratio of cost of revenue to the average of inventory and other current assets. This ratio indicates the efficiency of inventory management and the company's ability to convert inventory into sales within a specific period. A lower number of days in inventory is generally preferable.

NASDAQ: HLVX

Hillevax Inc

CEO	Dr. Robert M. Hershberg M.D., Ph.D.
IPO Date	April 29, 2022
Location	United States
Headquarters	75 State Street, Boston, MA, United States, 02109
Employees	90
Sector	Healthcare
Industry	Biotechnology

Description

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Key trends